Search all content on GOV.UK

Did you mean quercetin?

• Gelatine and collagen intended for human consumption: model health certificates

  Competent authorities of exporting countries should use the relevant model health certificate as a template to create a version exporters can apply for to export gelatine and collagen intended for human consumption to Great Britain, the Channel Islands or Isle...
• MHRA approves sebetralstat (Ekterly) to treat hereditary angioedema (HAE) attacks in patients aged 12 and over

  The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. 

  • Updated: 15 July 2025
• Class 4 Medicines Notification, Zentiva Pharma UK Limited, Various Products, EL(25)A/24

  Zentiva Pharma UK Limited has informed the MHRA of an issue related to batches of various soluble or effervescent tablets.

  • Updated: 2 June 2025
• Class 4 Medicines Notification, Chemidex Pharma Ltd, Various Products, EL(25)A/21

  Chemidex Pharma Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in their topical steroid products does not contain all the required safety information. Cartons for the products/batches listed are missing side effect information related to Visual Disturbances....

  • Updated: 13 May 2025
• Iron and ferritin accumulate in separate cellular locations in Phaseolus seeds
  • Updated: 1 January 2010
• Country policy and information note: medical treatment and healthcare, China, July 2022 (accessible)
  • Updated: 23 July 2025
• Authentication of chondroitin containing supplements

  Government Chemist publishes definitive approaches for the authentication of chondroitin

  • Updated: 28 February 2018
• Proposal to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies
  • Updated: 3 July 2023
• Product Safety Report: Kojic Clear Cream with Lemon sold via eBay (2301-0158)

  Product Safety Report for Kojic Clear Cream with Lemon presenting a serious chemical risk.

  • Updated: 16 February 2023
• Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk

  Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients taking fezolinetant. Fezolinetant should be avoided in...

  • Updated: 10 April 2025